Concord Biotech Intrinsic Value
Concord Biotech (CONCORDBIO) median intrinsic value is ₹2383.40 from 10 valuation models (range ₹464–₹3664), vs current price ₹1548.00 — +54.0% upside (Trading Below Calculated Value), margin of safety 35.1%. Read CONCORDBIO dividend payout details for the complete payout history and dividend yield track record.
CONCORDBIO Valuation Methods Summary — DCF, Graham Number & P/E
Concord Biotech intrinsic value across 10 models vs current price ₹1548.00 — upside/downside and value range per method. For current market price and key ratios, visit Concord Biotech stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹744.48 | ₹595.58 - ₹893.38 | -51.9% | EPS: ₹33.84, Sector P/E: 22x |
| Book Value Method | asset | ₹3663.64 | ₹3297.28 - ₹4030.00 | +136.7% | Book Value/Share: ₹1831.82, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2480.00 | ₹2232.00 - ₹2728.00 | +60.2% | Revenue/Share: ₹1240.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3096.00 | ₹2786.40 - ₹3405.60 | +100.0% | EBITDA: ₹536.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2383.40 | ₹1906.72 - ₹2860.08 | +54.0% | CF Growth: 6.4%, Discount: 15% |
| PEG Ratio Method | growth | ₹464.40 | ₹417.96 - ₹510.84 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹522.83 | ₹470.55 - ₹575.11 | -66.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹3096.00 | ₹2786.40 - ₹3405.60 | +100.0% | ROE: 17.7%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1180.99 | ₹1062.89 - ₹1299.09 | -23.7% | EPS: ₹33.84, BVPS: ₹1831.82 |
| Dividend Yield Method | dividend | ₹464.40 | ₹417.96 - ₹510.84 | -70.0% | DPS: ₹7.55, Target Yield: 2.5% |
CONCORDBIO Intrinsic Value vs Market Price — All Valuation Models
Concord Biotech fair value range ₹464–₹3664 vs current market price ₹1548.00 across 10 valuation models. Compare with CONCORDBIO fair price to assess whether the stock is under or overvalued.
CONCORDBIO Intrinsic Value Analysis — Undervalued or Overvalued?
Concord Biotech median intrinsic value ₹2383.40, current price ₹1548.00 — Trading Below Calculated Value by 54.0%, margin of safety 35.1%.
What is the intrinsic value of CONCORDBIO?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Concord Biotech (CONCORDBIO) is ₹2383.40 (median value). With the current market price of ₹1548.00, this represents a +54.0% variance from our estimated fair value.
The valuation range spans from ₹464.40 to ₹3663.64, indicating ₹464.40 - ₹3663.64.
Is CONCORDBIO undervalued or overvalued?
Based on our multi-method analysis, Concord Biotech (CONCORDBIO) appears to be trading below calculated value by approximately 54.0%.
CONCORDBIO Financial Health — Key Ratios vs Industry Benchmarks
Concord Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 24.51 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 17.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 36.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.61x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
CONCORDBIO Cash Flow Quality — Operating & Free Cash Flow
Concord Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹267 Cr | ₹196 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹245 Cr | ₹165 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹266 Cr | ₹189 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹246 Cr | ₹167 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹208 Cr | ₹152 Cr | Positive Free Cash Flow | 8/10 |